These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23286294)

  • 21. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
    Fiorucci S; Distrutti E
    Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cardiovascular pharmacology of COX-2 inhibition.
    Fries S; Grosser T
    Hematology Am Soc Hematol Educ Program; 2005; ():445-51. PubMed ID: 16304418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What price pain relief?
    Hochman JS; Shah NR
    Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335
    [No Abstract]   [Full Text] [Related]  

  • 24. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Solomon SD
    Curr Opin Cardiol; 2006 Nov; 21(6):613-7. PubMed ID: 17053413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
    Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
    Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
    Hermann M
    Praxis (Bern 1994); 2012 Oct; 101(20):1309-14. PubMed ID: 23032496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.
    Patrono C; Baigent C
    Mol Interv; 2009 Feb; 9(1):31-9. PubMed ID: 19299662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coxibs: a significant therapeutic opportunity.
    Gatti D; Adami S
    Acta Biomed; 2010 Dec; 81(3):217-24. PubMed ID: 22530460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [NSAIDs and cardiovascular and renal complications].
    Valat JP
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S3-4. PubMed ID: 17080562
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.
    ; Wilcox CM; Allison J; Benzuly K; Borum M; Cryer B; Grosser T; Hunt R; Ladabaum U; Lanas A; Paulus H; Regueiro C; Sandler RS; Simon L
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1082-9. PubMed ID: 16877048
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk-benefit perspectives in COX-2 blockade.
    Dabu-Bondoc S; Franco S
    Curr Drug Saf; 2008 Jan; 3(1):14-23. PubMed ID: 18690976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 inhibitors: a painful lesson.
    Sanghi S; MacLaughlin EJ; Jewell CW; Chaffer S; Naus PJ; Watson LE; Dostal DE
    Cardiovasc Hematol Disord Drug Targets; 2006 Jun; 6(2):85-100. PubMed ID: 16787194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Strand V
    Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective cyclooxygenase inhibitors: current status.
    Nandakishore R; Yalavarthi PR; Kiran YR; Rajapranathi M
    Curr Drug Discov Technol; 2014 Jun; 11(2):127-32. PubMed ID: 24467591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonsteroidal anti-inflammatory drugs and the heart: what is the danger?
    Mukherjee D
    Congest Heart Fail; 2008; 14(2):75-82. PubMed ID: 18401215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COX-2 selective inhibitors in the treatment of osteoarthritis.
    Laine L; White WB; Rostom A; Hochberg M
    Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.